Generate a tailored SOP for Dr. Zaklina Kovacevic. Improve your application with a focused, well-structured draft.
Dr. Zaklina Kovacevic completed her PhD in Medicine at the University of Sydney in 2011, focusing on developing a new class of metal-binding thiosemicarbazones as anti-cancer agents and elucidating the molecular mechanisms in various cancer types, including pancreatic, prostate, and breast cancers. She has actively contributed to understanding the function of the iron-regulated metastasis suppressor N-myc downstream regulated gene 1 (NDRG1) and its significant role in cancer progression and resistance to chemotherapies. In 2020, she established her independent research group at the University of Sydney and relocated to UNSW in 2023 to head the Tumour Microenvironment group within the School of Biomedical Sciences. Dr. Kovacevic's research focuses on the interaction between cancer cells and their tumor microenvironment, with particular interest in pancreatic cancer. She has published 81 research papers with over 5500 citations and has attracted more than $8.5 million in research grants, serving as the lead investigator for $3 million of that funding. She has been recognized with multiple awards, including the Premier's Award for Outstanding Cancer Research Fellow of the Year and the Sydney Medical School Award for Excellence in Early Career Research. Throughout her career, she has co-supervised 30 postgraduate students and is actively involved in peer review and grant assessment for national and international funding bodies.
University of New South Wales • Kensington, NSW, Australia
Teaching into undergraduate Medicine Physiology units and leading the Tumour Microenvironment research group.
Includes Business Intelligence, Enterprise Systems, and Cybersecurity Management streams.